International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients  Drucy Borowitz, Christopher Stevens,

Slides:



Advertisements
Similar presentations
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
Advertisements

Safety and efficacy of Creon® Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis  Nataliya Y. Kashirskaya, Nikolay I. Kapranov,
Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Karen Maguiness, Gavin.
Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
Abaigeal D. Jackson, Christopher H. Goss  Journal of Cystic Fibrosis 
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment.
Felix Ratjen, Paul Koker, David E
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
H. Grasemann, E. Tullis, F. Ratjen  Journal of Cystic Fibrosis 
Scott D. Sagel, Marci K. Sontag, Meg M
Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized,
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.
Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Early attained weight and length predict growth faltering better than velocity measures in infants with CF  Sonya L. Heltshe, Drucy S. Borowitz, Daniel.
Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis  C.J. Taylor, R. Thieroff-Ekerdt, S. Shiff, L.
Cirrhosis and other liver disease in cystic fibrosis
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection 
Pulmonary exacerbations in CF patients with early lung disease
Controlled clinical trials in cystic fibrosis — are we doing better?
Inhaled aztreonam lysine vs
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Laboratory parameter profiles among patients with cystic fibrosis
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized,
Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Karen Maguiness, Gavin.
A.H. Gifford  Journal of Cystic Fibrosis 
EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency  Jamie L. Wooldridge, James.
M. Wouthuyzen-Bakker, F.A.J.A. Bodewes, H.J. Verkade 
Demographics of glucose metabolism in cystic fibrosis
Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden  Per Kristian Knudsen, Hanne.
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A
Physiologic endpoints for clinical studies for cystic fibrosis
Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C
Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration  Drucy Borowitz, Daniel Gelfond, Karen.
E. Tschiedel, H. Grasemann, F. Ratjen  Journal of Cystic Fibrosis 
Nasal polyposis in lung transplant recipients with cystic fibrosis
Elliott C. Dasenbrook, Gregory S. Sawicki  Journal of Cystic Fibrosis 
Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint  M.W. Konstan, J.S. Wagener, A. Yegin, S.J.
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.
Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire  Joän M. Patterson, Melanie Wall, Jerica.
Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Steven D. Strausbaugh,
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS  Dorota Sands, Ewa Sapiejka, Grzegorz.
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
H. White, A.M. Morton, S.P. Conway, D.G. Peckham 
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis  C. Calabrese, A. Tosco, P. Abete, V. Carnovale,
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients  Gregory S. Sawicki, Will Chou, Karina.
The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled.
D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher 
Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.
CFTR modulators and pregnancy: Our work has only just begun
‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis
Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis  Ahmet Z. Uluer, David A. Waltz, Leslie.
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial  Michael W. Konstan, Patrick A. Flume, Matthias.
Volume 82, Issue 11, Pages (December 2012)
Alan Menter, MD, Stephen K
Presentation transcript:

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients  Drucy Borowitz, Christopher Stevens, Lee R. Brettman, Marilyn Campion, Barbara Chatfield, Marco Cipolli  Journal of Cystic Fibrosis  Volume 10, Issue 6, Pages 443-452 (December 2011) DOI: 10.1016/j.jcf.2011.07.001 Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 The international phase III randomized withdrawal, double-blind, placebo-controlled trial of the efficacy and safety of liprotamase in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). Trial design and subject disposition. Journal of Cystic Fibrosis 2011 10, 443-452DOI: (10.1016/j.jcf.2011.07.001) Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Mean change from baseline in coefficient of fat absorption (CFA) for CF subjects receiving liprotamase or placebo during the inpatient double-blind treatment phase of the trial, with stratification for baseline CFA, in (A) the entire intent-to-treat (ITT) population, (B) subjects who were continued from baseline on acid suppression versus subjects who did not receive acid suppression, and (C) subjects treated at US sites versus sites outside the United States. Journal of Cystic Fibrosis 2011 10, 443-452DOI: (10.1016/j.jcf.2011.07.001) Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Adjusted mean change from baseline in coefficient of fat absorption (CFA) stratified by baseline CFA level for CF subjects receiving liprotamase or placebo during the inpatient double-blind treatment phase of the trial. Values are least square means (LSM) plus standard error (SE). Journal of Cystic Fibrosis 2011 10, 443-452DOI: (10.1016/j.jcf.2011.07.001) Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions